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Abstract
Neurological syndromes occur in a significant number of patients with antiphospholipid antibodies. The
optimal management for these patients however remains uncertain.
Our study is a descriptive analysis looking retrospectively at 45 patients who presented to the principal
tertiary referral centre in the Australian Capital Territory, with either cerebral arterial or venous
thrombosis for which there was no obvious cause for their presentation when initially reviewed. The
diagnosis was based on the clinical findings made by one of three neurologists attached to our centre.
Radiological findings and the presence of either IgM or IgG anticardiolipin antibodies, IgG anti-beta-2
glycoprotein 1 antibodies or a lupus anticoagulant were then documented.
In this group of patients three subgroups were identified:
1. Individuals that fulfilled the Sapporo Classification Criteria
2. Individuals with transiently positive antiphospholipid antibodies and
3. Individuals with persistently low positive antiphospholipid antibodies.
The most interesting of these three groups are those individuals with transiently positive antiphospholipid
antibodies. A potential cause for presentation was identified in only one patient of this group with
documented infective endocarditis and bacteraemia. Comparison with the other two groups suggested
that there was little in terms of clinical presentation, radiological findings or intercurrent risk factors for
thrombotic disease to distinguish between them. With disappearance of antiphospholipid antibodies, the
individuals within this group have not had further thrombotic events.
Our observations emphasise the problems that continue to exist in relation to the occurrence of
cerebrovascular disease in the context of antiphospholipid antibodies and the optimal management of
these stratified groups. Our findings also raise an as yet unanswered question as to the signficance of these
transiently positive antiphospholipid antibodies. In the absence of significant intercurrent risk factors our
findings would suggest that in the group we describe that they are likely to be of clinical significance.
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Background
The antiphospholipid syndrome (APS) is an autoimmune
disorder characterised by recurrent venous and arterial
thromboses, recurrent foetal loss and spontaneous abor-
tions, thrombocytopenia, and the presence of antiphos-
pholipid antibodies [1,2]. While there is an association
with other autoimmune diseases such as systemic lupus
erythematosus, the condition may also arise independ-
ently of other autoimmune disorders [1,3,4]. The pres-
ence of antiphospholipid antibodies may also occur as
associated epiphenomena related to intercurrent infec-
tions and in this setting are said to be less likely to be asso-
ciated with the characteristic syndrome [5]. Furthermore,
a number of individuals with high titre anticardiolipin
antibodies do not develop APS and studies suggest that
additional factors or a "second hit" are required to cause
endothelial dysfunction and activation of a pro-coagulant
phenotype [6,7].
Neurological syndromes occur in a significant proportion
of individuals with antiphospholipid antibodies and
include transient ischaemic attacks, stroke (either embolic
or thrombotic), cerebral venous thrombosis, migraines,
seizures, multi-infarct dementia and mononeuritis multi-
plex [2,8-10]. With strong evidence that appropriate treat-
ment with anticoagulant therapy is effective in
minimising both arterial and venous thrombotic disease
in these individuals [11,12], it is important to be able to
identify individuals with APS at the time of presentation.
Classification, but not clinical diagnosis is assisted by the
Sapporo criteria, a preliminary classification formulated
in 1999. In these criteria, venous or arterial thrombotic
vascular disease is essential. The criteria currently mandate
repeating antibody tests after 6 weeks [13]. This presents a
problem where an acute diagnosis has implications for
initiating active therapy.
While a firm evidence base is accumulating for the man-
agement of venous thrombosis and recurrent pregnancy
loss in APS, the same cannot be claimed for cerebrovascu-
lar disease, which remains a problematic area with a
number of unanswered questions.
This study involved the descriptive analysis of all patients
presenting to a single centre with either cerebral arterial or
venous thrombosis where a cause could not clearly be
identified at the time of presentation. The presence of IgM
or IgG anticardiolipin (aCL) antibodies, IgG anti-beta-2-
glycoprotein1 (anti-β2GP1) antibodies and/or a lupus
anticoagulant and results of radiological imaging were
documented.
This series of patients illustrates each of the above conun-
drums, and emphasises the difficulty in clear-cut decision-
making.
Methods
Patients were selected consecutively on the basis of admis-
sion to The Canberra Hospital, the principal tertiary refer-
ral hospital for the Australian Capital Territory and
surrounding south east New South Wales, with a total
population of approximately 500,000, between January 1,
1995 to May 31, 2003 inclusive, with clinical or radiolog-
ical evidence of cerebral infarction and the presence of
IgM or IgG aCL antibodies, IgG anti-β2GP1 antibodies
(when this assay became routinely available at our centre
in 2000) and/or lupus anticoagulant. Initial events were
recorded back to 1975 and therefore in some individuals
the diagnosis was made retrospectively, in that aCL were
not routinely tested for until 1986. Currently, in this insti-
tution, patients are further investigated for the presence of
prothrombotic factors including AT-III, protein C and
protein S deficiencies in addition to prothrombin
G20210A and Factor V Leiden mutations, where there are
no identifiable causes for their presentation with either
cerebral venous or arterial thrombosis. Over the study
period January 1, 1995 to May 31, 2003, 1729 patients
were admitted to The Canberra Hospital with cerebral inf-
arction.
Following selection, clinical data were retrospectively and
prospectively reviewed. For each patient the clinical find-
ings were confirmed by examination by one of three neu-
rologists. A number of other parameters were assessed
including: intercurrent risk factors for vascular disease –
hypertension, hyperlipidemia, tobacco use, obstructive
sleep apnoea [14] – the presence of other procoagulant
factors, the use of the combined oral contraceptive pill, a
history of previous miscarriage, intrauterine growth retar-
dation or pre-eclampsia and previous arterial or venous
thrombotic events. Results of cerebral imaging, including
computed tomography (CT) and magnetic resonance
imaging (MRI), in addition to echocardiography and
carotid duplex ultrasound, were collated. Follow-up
antiphospholipid testing, ideally at least 6 weeks apart as
defined in the Sapporo criteria [13] was collected where
possible. Information regarding the therapy instituted at
the time of diagnosis and long-term follow-up was
obtained.
Laboratory tests
IgM and IgG aCL antibodies were detected by a semi-
quantitative enzyme-linked immunoabsorbent assay
according to the manufacturer's instructions using a com-
mercially available kit (Immuno Concepts RELISA, Sacra-
mento, CA, USA). The test system is standardised using
internationally recognised reference preparations
obtained from the Antiphospholipid Standardisation
Laboratory. Results were reported semi-quantitatively
according to the manufacturer's instructions in standard-
ised units as follows: negative (IgG, <8 G phospholipidJournal of Autoimmune Diseases 2006, 3:3 http://www.jautoimdis.com/content/3/1/3
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Table 1: Summary of clinical details for three groups of patients with aCL presenting with neurological events.
Demographics Patients fulfilling Sapporo 
classification criteria
Group with transiently 
positive aCL
Group with low positive 
aCL
Number of patients N = 26 N = 7 N = 12
Median age (years) 37.6 (6–63) 35.4 (16–51) 41.6 (19–59)
Number of episodes/patient
11 9 4 6
27 3 6
Clinical presentations N = 33 N = 10 N = 18
Superior sagittal sinus thrombosis 1 1 -
Higher centre function loss 3 1 1
Left hemiparesis/paraesthesia 10 5 6
Right hemiparesis/paraesthesia 6 - 2
Brainstem/cerebellar symptoms 5 - 5
Loss of consciousness/seizures 4 - 1
Fluent aphasia, right facial weakness 1 - -
Bilateral cerebral infarction - 1 -
Cranial nerve palsies 1 2 1
Right homonymous hemianopia 1 - 1
Transient ischaemic attacks 1 - 1
Radiological findings N = 26 N = 7 N = 12
No abnormalities on CT or MRI scan 2 3 6
Left middle/posterior cerebral artery 
territory infarction
4-2
Right middle/posterior cerebral artery 
territory infarction
4--
Low density area (left temporal lobe) 2 - -
Increased signal cerebral deep white 
matter
312
Pontine/cerebellar infarction 2 1 1
Multiple cerebral infarcts 9 - 1
Superior sagittal sinus thrombosis - 1 -
Bilateral narrowing of carotid syphons - 1 -
Antiphospholipid studies:
IgM aCL 6 moderate -high positive - 3 low positive
IgG aCL 18 moderate -high positive 1 low positive, 1 moderate 
positive
6 low positive, 3 moderate 
positive
Lupus anticoagulant KCT 9 4 2
Lupus anticoagulant DRVVT 9 6 2
Low to moderate IgG anti-
β2GP1antibodies
7/12 (data incomplete) 1 low positive 1 low positive
Risk factors for vascular disease
Hypercholesterolaemia 3 - 4
Hypertension 4 1 3
Tobacco use 3 2 3
Oral contraceptive pill/hormone 
replacement therapy
6-1
Pregnancy/post-partum period 2 1 -
Heterozygosity for factor V Leiden 
mutation
1-
Long term warfarin 19 2 -
Warfarin (six months) -11
Low dose aspirin 64 1 0
Clopidogrel/ticlopidine 1-1Journal of Autoimmune Diseases 2006, 3:3 http://www.jautoimdis.com/content/3/1/3
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units (GPL units), IgM, <8 M phospholipid units (MPL
units); low positive (IgG, 8–20 GPL units; IgM 8–20 MPL
units); medium positive (IgG, 20–80 GPL units; IgM 20–
80 MPL units) and high positive (IgG, >80 GPL units; IgM,
>80 MPL units). IgG anti-β2GP1 antibodies were also
detected by a semi-quantative enzyme-linked assay
according to the manufacturer's instructions using a com-
mercially available kit (QUANTA Lite, San Diego, CA,
USA). Results were reported semi-quantitatively in stand-
ard IgG anti-β2GP1 units (SGU) as follows: positive (IgG,
> 8 SGU); The system was standardised using a set of ref-
erence calibrators available from the Rheumatology Labo-
ratory, Seton Hall University, St Joseph's Hospital and
Medical Centre (New Jersey, USA) and supplied with the
commercial kit.
Lupus anticoagulants (LA) are a group of antibodies that
interfere with phospholipid-dependent coagulation reac-
tions. In the laboratory they are defined as prolonged clot-
ting tests that are responsive to procoagulant
phospholipids. By definition, the tests should not correct
with the addition of normal plasma but are corrected by
the addition of phospholipid. In our laboratory the
diluted Russell's viper venom time (dRVVT) and kaolin
clotting time (KCT) are used to detect LA [15]. The dRVVT
is used as a screening test using a commercial kit (Gradi-
pore, French's Forest, Australia). A mixing test is per-
formed on all positive LA screen results, that is, the
clotting time is 20% longer than the pooled platelet poor
normal plasma (PNP). If the mixing test does not correct,
a LA Confirm test is performed to confirm the presence of
LA. The additional phospholipid in LA Confirm neutral-
ises lupus anticoagulants to give a normal clotting time.
The KCT is performed as per the method described in Gib-
son et al [16], where the difference in seconds between the
neat pool (10:0) and the 8:2 mixture of PNP: patient is
less than 20% different from the pooled normal plasma,
the sample is considered negative. Where the difference is
20% or greater then the results are graphed on a six-point
curve and the shape of the curve analysed. In the presence
of LA the curve should be convex in the region near the Y-
axis. A platelet neutralisation procedure is then performed
to confirm the presence of a lupus anticoagulant. In this
procedure a frozen-thawed platelet solution is added to
the kaolin clotting time mixture to provide a source of
platelet phospholipid able to overcome the effects of a
lupus anticoagulant. With comparison to a normal
pooled plasma clotting time, normalisation of the clotting
time, confirms the presence of a lupus anticoagulant.
Antiphospholipid studies were repeated at least six weeks
after the initial study. There have been no concerns regard-
ing the performance of these assays in the routine quality
assurance program for diagnostic laboratories in Australia
run by the Royal College of Pathologists of Australasia
(RCPA) and the National Association of Testing Authori-
ties and conform with the consensus guidelines devel-
oped by the aCL Working Party comprising members of
the Immunology Advisory, Quality Assurance and Scien-
tific Education Committees of the RCPA [17].
Results
Data were collected for 52 patients and 6 were immedi-
ately excluded because follow-up serology was not availa-
ble. A further patient with infective endocarditis and
therefore a potential cause for the presence of aCL was
also excluded from further analysis. Of the remaining 45
the median age was 38.2 years with the age ranging from
6–63 years. There were 32 females and 13 males. Three
groups of patients were identified on the basis of the
results of antiphospholipid antibody testing.
In the first group of patients with primary antiphospholi-
pid syndrome, 26 had completed strokes while seven of
this group had had more than one stroke (two patients
after anticoagulation with warfarin had been com-
menced). Multiple sites of the brain were involved and
there was evidence for an embolic source in 8 patients.
The clinical details for this group are summarised in Table
1. Twenty of the twenty-six patients were commenced on
long-term high intensity warfarin therapy [11,12], either
at the time of presentation or in the post-partum period.
While some patients were originally diagnosed with
obstetric antiphospholipid syndrome, their presentation
was complicated by cerebral infarction or were noted on
review during admission to have radiological evidence of
past cerebral infarction. In those patients who had con-
traindications to the use of warfarin – three received low
dose aspirin (100 mg daily), while the fourth individual
was treated with clopidogrel at the standard dose (75 mg
daily).
Only four patients in this group have had further throm-
botic episodes since warfarinisation. The four individuals
were on long-term warfarin but in all four cases the INR
had fallen to less than 3.0 in the period prior to their pres-
entation with a thrombotic event. Three of these patients
had additional arterial thrombotic events. One presented
with both a stroke and pulmonary embolus, while two
patients had further strokes and these have been included
in the study. The last patient presented with a deep venous
thrombosis involving the right lower limb. The duration
of sub-therapeutic INR's prior to presentation in these
individuals however could not be determined due to
infrequent monitoring; however there have been no fur-
ther recorded recurrences subsequent to these events.
The group with disappearing aCL comprised seven
patients and details are summarised in Table 1. On repeat
testing antiphospholipid antibodies could not be detectedJournal of Autoimmune Diseases 2006, 3:3 http://www.jautoimdis.com/content/3/1/3
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in any of these patients by all assays currently performed
in our laboratory. Where possible these tests were per-
formed at least six weeks after the initial tests, but in some
cases were performed up to one year after initial testing.
Repeated assays including LAC have remained negative
and all of this group have been tested on four separate
occasions albeit at differing time intervals. Only one in
this group had a potential cause identified for the presen-
tation with documented intercurrent infection. Strepto-
coccus viridans was isolated from blood cultures and
mitral valve vegetations demonstrated at echocardiogra-
phy. This patient was therefore excluded from further
analysis and is not included in the table. In this group,
three patients received either low dose aspirin or clopi-
dogrel where aspirin was contraindicated.
The third group comprised 12 patients with persistent low
positive aCL antibodies on the basis of follow up testing
at least six weeks after the initial testing and clinical data
are summarised in Table 1. Within this particular group
there were no clear distinguishing factors on the basis of
the clinical presentation. Six of the twelve individuals
experienced two distinct neurological events. Within the
group of twelve, six had additional risk factors for vascular
disease of which five had one or two associated risk factors
for vascular disease, respectively. Four of the six individu-
als with additional risk factors had radiological evidence
of completed strokes. The majority of individuals in this
group have continued on low dose aspirin.
Discussion
The three different groups of patients described emphasise
a number of problems that exist in relation to the occur-
rence of cerebrovascular disease and antiphospholipid
antibodies.
Current standard practice for patients with APS is to rec-
ommend indefinite anticoagulation with warfarin. This is
derived from a limited experience with arterial thrombo-
sis, a much larger and more definitive experience with
venous thrombosis and the observations by many groups
that these patients are prone to recurrent cerebrovascular
events which, in principle, should be preventable [11,12].
In these studies venous and arterial disease is not clearly
separated and comparison between different forms of
recurrence prevention is limited [18].
The Antiphospholipid Antibody Stroke Study (APASS), a
prospective cohort study within the Warfarin vs. Aspirin
Recurrent Stroke Study (WARSS) does not provide
answers for the management of the syndrome but chal-
lenges the current practice of long duration warfarin.
However, the patients in this study were not representa-
tive of those described here, or in other series of cerebrov-
ascular disease and APS. They were generally of advanced
years, the aCL cut-off was much lower than the Sapporo
criteria demand and the target INR of 2.0 lower than that
recommended for APS. While the subgroup of patients
with both LA and aCL had a greater risk for thrombo-
occlusive events and appeared to derive benefit from war-
farin, no other group did, nor did the patients overall [19].
Patients with embolic disease were excluded from WARSS
and this study and most others provide little guidance on
how to deal with the patients reported here, especially the
problem of how to prevent recurrent ischaemic events.
There is no guidance on how to approach a patient as a
primary event and whether early diagnosis and manage-
ment will make a difference to the ultimate outcome. Cur-
rently, the diagnosis is generally made after the critical
cerebrovascular event is well under way, often recovering.
To seriously consider how to manage these patients
acutely the diagnosis would have to be appropriately
acute as well.
The three groups here raise some very interesting ques-
tions. Twenty-six patients satisfy the Sapporo criteria and
are quite similar to other such series of patients described
previously. The range of antibody tests and the nature of
the cerebrovascular lesions has the same broad spectrum
as has been previously described [6,15]. Based on previ-
ous experience, steps need to be taken to reduce the recur-
rence rate and in this series warfarin was generally used
unless contraindicated. This is in agreement with the prac-
tice of others [11,12,20] although there is no clear consen-
sus as to the optimal treatment of these patients [21] with
the findings of Crowther et al [22]challenging the need for
high intensity anticoagulation, demonstrating that the
absolute risk of recurrent thrombosis was low where the
INR was maintained at 2.0–3.0. A more recent by Finazzi
et al[23] reported similar results with high-intensity war-
farin (INR 3.0 – 4.5) conferring no advantage over stand-
ard treatment (INR 2.0 – 3.0) in the prevention of
recurrent thrombosis in individuals with antiphospholi-
pid syndrome and was associated with an increased risk of
minor haemorrhage. Both of these studies however,
excluded patients with a history of recurrent thrombosis
anticogulant therapy and therefore looked at a group
likely to be a lower risk of recurrent events. In Crowther et
al's study, individual's allocated to the high intensity
group were below the target range 43% of the time. Three
of the six individuals had an INR < 3.0 at the time of
thrombosis while a fourth had ceased warfarin 137 days
prior to the event [22] (reviewed in [24]). It is unclear
from the second study as to how frequently those allo-
cated to the high intensity group were sub-therapeutic but
the mean INR of 3.2 would suggest that at least some indi-
viduals were sub-therapeutic throughout the time of the
study. These studies therefore do not necessarily refute the
findings of previous groups that high intensity warfarinJournal of Autoimmune Diseases 2006, 3:3 http://www.jautoimdis.com/content/3/1/3
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may confer a benefit in those at high risk of recurrent
thrombosis.
On the basis of the results of the Stroke Prevention in
Reversible Ischemia Trial which found that high intensity
anticoagulation (INR 3.0 – 4.5) was associated with an
increased risk of major bleeding including cerebral haem-
orrhage [25,26], in addition to the small study by al-
Sayegh [27] detailing haemorrhagic complications in a
small group of patients with primary and secondary
antiphospholipid syndrome, other groups have chosen to
use low dose aspirin as prophylactic treatment in individ-
uals with antiphospholipid syndrome who present with
ischaemic stroke [28]. In our group however, 3 of the 8
patients developed further thrombotic disease while on
low dose aspirin, two had recurrent strokes while the third
had a spontaneous deep venous thrombosis. All three
were subsequently treated with warfarin. However, it is
difficult to draw conclusions based on on our study or
those of al-Sayegh [27] and Derksen [28], due to their
small size and lack of statistical power.
Patients in the second group at the time that the first lab-
oratory tests became available could not be individually
distinguished from those in the first group in contrast to
observations in a group of patients with systemic lupus
erythematosus where anti-β2GP1 antibodies were noted
to drop at the time of thrombosis [29]. At the initial pres-
entation, it would be reasonable to manage them in the
same way, that is, anticoagulate, however with follow-up,
this was probably unnecessary as the antibodies proved
short-lived and the Sapporo classification criteria were not
met. An alternative approach would be to wait in all
patients until the Sapporo criteria are met – that is, defer
a decision on definitive anticoagulation for six weeks.
Given that the risk of recurrence is probably higher early
on and community based studies suggest that the highest
risk is in the first year with a mortality rate of 15–20%
within the first 30 days following the initial stroke
[30,31], this option is not seen as attractive. Either way,
when faced with the patient, especially a young patient,
with a cerebrovascular event and a criteria-positive
antiphospholipid antibody there is clearly a dilemma.
This subgroup which we believe has not been so clearly
defined before would have to be considered in any future
therapeutic study.
The third group also poses a problem and do not fulfill
the classification criteria for antiphospholipid syndrome,
as the antibody levels are insufficient to meet the Sapporo
criteria. Those without radiological abnormalities might
have had migraine equivalents, but the other patients,
about half with definite radiological abnormalities and
low level antibodies, had very few other risk factors. While
two patients within this group were given six months of
warfarin, the remainder were treated with low dose aspi-
rin. None of these patients have had a recurrence to date,
with a variable follow-up of 16 months -10 years. What
indeed did they have and how should they be managed?
Although in serological terms these patients resemble
those of the APASS study [19], they are generally much
younger. In the Stroke Prevention in Young Women Study
[32], where the population studies included women aged
between 15 and 44 years of age presenting with a first epi-
sode of ischaemic stroke, the presence of any anticardiol-
ipin isotype or LA was associated with an increased risk of
recurrent stroke with an overall relative odds ratio (OR) of
1.87 (95% CI, 1.24–2.83, P = 0.0027). However,
antiphospholipid studies were only performed on one
occasion and in some cases at a time distant to the stroke.
The third group reported here is hard to directly compare
to these patients, but could potentially overlap substan-
tially with the patients described by Brey et al [32], where
over half the patients had low positive antiphospholipid
antibodies. Although excluded from the Sapporo criteria
these patients would be important in any future study,
warfarin was rarely used in patients in this group in our
series.
This study has several limitations as it is essentially a
descriptive study and is therefore open to bias given that
the authors were not blinded when assessing the patients
included in the study. The utility of the data is also ham-
pered by a lack of standardisation in the approach to treat-
ment. The assays used for assessing for the presence of aCL
changed in 2000 and it is possible that some individuals
may have become negative because a different assay was
used. Additionally, in some individuals, the diagnosis was
based on collection of retrospective data and there is no
comparative group without antiphospholipid antibodies
resulting in further sources of potential bias.
However, a strength of this study is that it represents what
is actually done in a tertiary care centre in the face of con-
flicting evidence. We believe that such experience is worth
reporting, reflecting as it does the realities of medical prac-
tice and serving as a useful adjunct to the gold standard
randomised, double blinded trial.
We conclude that in our population, this combined retro-
spective and prospective analysis, confirms that recurrent
events occur in young patients with cerebrovascular
events and antiphospholipid antibodies. It does not pro-
vide information about the optimum method of prevent-
ing recurrence. Ultimately we believe there must be a
much larger study of treatment and secondary prevention
studies in stroke, with either emergency diagnosis of
phospholipid antibody status, or a nested part of a much
larger study with stratification of patients into at least the
three categories described here.Journal of Autoimmune Diseases 2006, 3:3 http://www.jautoimdis.com/content/3/1/3
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